Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Semen quality in hypogonadal acromegalic patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christoph Wanner
  • Ulla Feldt-Rasmussen
  • Ana Jovanovic
  • Aleš Linhart
  • Meng Yang
  • Elvira Ponce
  • Eva Brand
  • Dominique P Germain
  • Derralynn A Hughes
  • John L Jefferies
  • Ana Maria Martins
  • Albina Nowak
  • Bojan Vujkovac
  • Frank Weidemann
  • Michael L West
  • Alberto Ortiz
Vis graf over relationer

AIMS: Long-term treatment effect studies in large female Fabry patient groups are challenging to design because of phenotype heterogeneity and lack of appropriate comparison groups, and have not been reported. We compared long-term cardiomyopathy and kidney function outcomes after agalsidase beta treatment with preceding treatment-naive outcomes.

METHODS AND RESULTS: Self-controlled pretreatment and post-treatment comparison (piecewise mixed linear modelling) included Fabry female patients ≥18 years at treatment initiation who received agalsidase beta (0.9-1.1 mg/kg every other week) for ≥2 years, with ≥2 pretreatment and ≥2 post-treatment outcome measurements during 10-year follow-up. Left ventricular posterior wall thickness (LVPWT)/interventricular septal thickness (IVST) and estimated glomerular filtration rate (eGFR, Chronic Kidney Disease Epidemiology Collaboration creatinine equation) analyses included 42 and 86 patients, respectively, aged 50.0 and 46.3 years at treatment initiation, respectively. LVPWT and IVST increased pretreatment (follow-up 3.5 years) but stabilized during 3.6 years of treatment (LVPWT: n = 38, slope difference [95% confidence interval (CI)] = -0.41 [-0.68, -0.15] mm/year, Ppre-post difference <0.01; IVST: n = 38, slope difference = -0.32 [-0.67, 0.02] mm/year, Ppre-post difference = 0.07). These findings were not modified by renal involvement or antiproteinuric agent use. Compared with the treatment-naive period (follow-up 3.6 years), eGFR decline remained modest and stabilized within normal ranges during 4.1 years of treatment (slope difference, 95% CI: -0.13 [-1.15, 0.89] mL/min/1.73m2 /year, Ppre-post difference = 0.80).

CONCLUSIONS: Cardiac hypertrophy, progressing during pretreatment follow-up, appeared to stabilize during sustained agalsidase beta treatment. eGFR decline remained within normal ranges. This suggests that treatment may prevent further Fabry-related progression of cardiomyopathy in female patients and maintain normal kidney function.

OriginalsprogEngelsk
TidsskriftESC Heart Failure
Vol/bind7
Udgave nummer3
Sider (fra-til)825-834
Antal sider10
ISSN2055-5822
DOI
StatusUdgivet - jun. 2020

Bibliografisk note

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

ID: 59977866